Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.82 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.82 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.82 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.82 |
| ▸ | UBA1 | P22314 | 1/20 | 0.82 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.82 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Largazole SCHEMBL31485751 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL91139 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL2611944 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL23760414 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL71330 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL23760411 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL10314988 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL2611945 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL14973971 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 | |
| Largazole SCHEMBL7937167 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357708-B2 | Macrocyclic compounds and methods of treatment | University of Florida Resesarch Foundation, Inc. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120095065-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8129418-B2 | Macrocyclic compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095065-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | MKI67, MCL1, MYC | HDAC1 157/4885HDAC3 79/4885HDAC2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.